NCT01170871撤回1 期
Phase I Clinical Trial of Ixabepilone and Pemetrexed in Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- To determine the maximal tolerated dose (MTD) of Ixabepilone and Pemetrexed in advanced solid tumors.
研究概览
简要总结
The purpose of the study is to determine the maximal tolerated dose (MTD) of Ixabepilone and Pemetrexed in advanced solid tumors and to obtain preliminary information regarding the activity of this combination.
This research study is for research participants who have confirmed metastatic or unresectable solid tumors (lung, breast, ovary, cervix, uterus, mesothelioma, and prostate) for which standard curative or palliative measures do not exist or no longer effective.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •SWOG performance status of 0-
- •Projected life expectancy of at least 3 months.
- •Female and or male age 18 years and over.
- •Provision of informed consent prior to any study-related procedures.
- •Female patients must not be pregnant due to the potential mutagenicity. and teratogenicity of this treatment. A pregnancy test must be administered 7 days prior to administration of therapy to women of childbearing potential.
- •Negative pregnancy test for women of childbearing potential.
- •Patients must agree to use some form of contraception while on this study at initiation and for the duration of participation in the study. Sexually active males must also use a reliable and appropriate method of contraception. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •Patients must have recovered from acute toxicities from previous surgery, chemotherapy or radiation therapy.
- •Adequate organ function defined as:
- •ANC > 1500/mm3
- •Platelet count > 100,000 cells/mm3
- •Hemoglobin > 9.0g/dL
- •Serum creatinine < 1.5 mg/dl or creatinine clearance > 45 mL/minute
- •(calculated by Cockcroft-Gault formula.)
- •Hepatic function: Patients must have adequate liver functions: AST or ALT < 2.5 X upper limit of normal (ULN), alkaline phosphatase < 2.5 X upper limit of normal. In patients with bone metastasis and no evidence of liver metastasis and bilirubin < upper limit of normal an alkaline phosphatase < 5 ULN will be allowed
- •Serum Bilirubin < 1.5 mg/dL
- •Peripheral neuropathy grade 0-
- •No other concomitant therapy directed at the cancer is allowed.
- •The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed.
- •The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol.
排除标准
- •Laboratory results:
- •Serum bilirubin > 1.5 the upper limit of reference range (ULRR)
- •Serum creatinine >1.5 x ULRR or creatinine clearance < 45 mL/minute (calculated by Cockcroft-Gault formula)
- •Women who are currently pregnant or breast feeding.
- •Receipt of any investigational agents within 30 days prior to commencing study treatment.
- •Last dose of prior chemotherapy discontinued less than 4 weeks before the start of study therapy.
- •Last radiation therapy within the last 4 weeks before the start of study therapy, except palliative radiotherapy.
- •Prior radiation must not have included ≥ 30% of major bone marrow containing areas (pelvis, lumbar spine).
- •Any unresolved toxicity greater than CTC grade 1 from previous anti- cancer therapy, excluding alopecia.
- •CTC Grade 1 or greater neuropathy (motor or sensory) at study entry.
- •Hematologic function with absolute neutrophils ≤ 1500/mm3 and/or platelets < 100,000/mm
- •Hepatic function with serum bilirubin greater than the upper institutional limits of normal, ALT and AST > 2.5 times the upper institutional limits of normal.
- •Presence of third space fluid which cannot be controlled by drainage.
研究组 & 干预措施
Experimental
Experimental
Escalating doses of Ixabepilone and Pemetrexed
干预措施: Ixabepilone (Drug)
Experimental
Experimental
Escalating doses of Ixabepilone and Pemetrexed
干预措施: Pemetrexed (Drug)
结局指标
主要结局
To determine the maximal tolerated dose (MTD) of Ixabepilone and Pemetrexed in advanced solid tumors.
时间窗: weekly
次要结局
- Response Rate(every 42 days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast CancerBreast CancerNCT00568022R-Pharm9
已完成
1 期
Study of Ixabepilone (BMS-247550) in Patients With Solid TumorsSolid TumorsNCT01018966R-Pharm25
已完成
1 期
Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)NCT00683904R-Pharm12
已完成
1 期
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.Solid MalignanciesNCT00162136R-Pharm35
已完成
1 期
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast CancerMetastatic Breast CancerNCT00924352Accelerated Community Oncology Research Network56